Paul Spagnuolo advances nutrition‑derived small‑molecule therapeutics across metabolism and cancer. He holds an issued patent on avocatin B and has moved candidates from discovery to randomized clinical safety evaluation, with applications in leukemia, bone marrow protection and metabolic disease.